Efficacy of Fibrin Sealants in Preventing Seroma Formation in Reduction Mammaplasty: A Single Surgeon's Experience.

Annals of plastic surgery 2020 Vol.85(S1 Suppl 1) p. S41-S43

Marquez JE, Kapadia K, Ghosh K, Silvestri B, Singh G, Huston TL

관련 도메인

Abstract

[BACKGROUND] Fibrin sealant is a controversial method for reducing seroma formation. It is comprised of human proclotting factors, fibrinogen and thrombin. Fibrin sealants have been extensively studied for their efficacy in reducing the rates of seroma by sealing the dead space; however, in most studies, the sealants are used with surgical drains. According to the U.S. Food and Drug Administration, fibrin sealant carries the risk of life-threatening thromboembolic complications, gas emboli, and transmission of infectious agents. Despite these concerns, many plastic surgeons use such products in ambulatory surgeries even though its effect on seroma formation has yet to be elucidated. The aim of our study is to determine the efficacy of fibrin sealants in seroma prevention in reduction mammoplasty with and without surgical drains.

[METHODS] A retrospective chart review was performed of all bilateral reduction mammaplasty by a single-surgeon from 2014 to 2018. Patients had at least 90 days postoperative follow-up. Exclusion criteria consisted of patients younger than 18 years, had prior breast surgery, or had an incidental cancer diagnosis in breast reduction tissue specimen.

[RESULTS] On analysis, 159 patients met inclusion criteria and were categorized into group 1, with fibrin sealant (n = 101) and group 2, no fibrin sealant (n = 58). There were no statistical differences in patient demographics. There was no significant difference in the incidence of seroma between group 1 and group 2 (21% vs 19%, P = 0.782). Group 1 incidence of seroma was further analyzed by sealant type: Tisseal, Floseal, and Evicel (12% vs 27% vs 23%, P = 0.436). In group 1, the use of sealant alone was more likely to result in seroma formation when compared with the combination of sealant and surgical drains (25% vs 8%, P = 0.069).

[CONCLUSIONS] There is no difference in rate of seroma formation with the use of fibrin sealants in reduction mammaplasty. The use of fibrin sealants without surgical drains may increase the rate of seromas. Plastic surgeons could consider weighing the risk versus benefits in using fibrin sealants with or without drains in ambulatory surgeries.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
합병증 seroma 장액종 dict 9
시술 mammaplasty 유방성형술 dict 3
해부 breast 유방 dict 2
시술 reduction mammoplasty 유방성형술 dict 1
시술 breast reduction 유방성형술 dict 1
해부 bilateral scispacy 1
해부 tissue scispacy 1
합병증 emboli scispacy 1
합병증 seromas scispacy 1
약물 fibrinogen C0016006
fibrinogen
scispacy 1
약물 [BACKGROUND] Fibrin scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 thromboembolic C0333214
thromboembolic
scispacy 1
질환 cancer C0006826
Malignant Neoplasms
scispacy 1
질환 seromas C0262627
Seroma
scispacy 1
질환 Tisseal scispacy 1
기타 Fibrin Sealants scispacy 1
기타 human scispacy 1
기타 fibrinogen scispacy 1
기타 thrombin scispacy 1
기타 Fibrin scispacy 1
기타 Patients scispacy 1
기타 patient scispacy 1

MeSH Terms

Female; Fibrin Tissue Adhesive; Humans; Mammaplasty; Postoperative Complications; Retrospective Studies; Seroma; Surgeons

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문